Elicera Therapeutics AB
STO:ELIC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Elicera Therapeutics AB
STO:ELIC
|
SE |
|
Sun Race Sturmey-Archer Inc
TWSE:1526
|
TW |
|
BWX Ltd
ASX:BWX
|
AU |
|
K
|
KAISA JiaYun Technology Inc
SZSE:300242
|
CN |
|
Sunopta Inc
TSX:SOY
|
CA |
|
OZ Minerals Ltd
ASX:OZL
|
AU |
|
D
|
Dongzhu Ecological Environment Protection Co Ltd
SSE:603359
|
CN |
|
Atomo Diagnostics Ltd
ASX:AT1
|
AU |
Elicera Therapeutics AB
Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
